Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Hecht, Randy ^a   Li, Yue Sheng ^a   Sun, Jeonghoon ^a   Belouski, Ed ^a   Hall, Michael ^a   Hager, Todd ^a   Yie, Junming ^a   Wang, Wei ^a   Winters, Dwight ^a   Smith, Stephen ^a   Spahr, Chris ^a   Tam, Lei Ting ^a   Shen, Zhongnan ^a   Stanislaus, Shanaka ^a   Chinookoswong, Narumol ^a   Lau, Yvonne ^a   Sickmier, Allen ^a   Michaels, Mark Leo ^a   Boone, Thomas ^a   Véniant, Murielle M ^a   Xu, Jing ^a   more..

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ARGININE; GLUCOSE; GLYCINE; HYBRID PROTEIN; IMMUNOGLOBULIN G1; KLOTHO PROTEIN; LEUCINE; LONG ACTING DRUG; PROLINE; RECOMBINANT IMMUNOGLOBULIN G1 FC FRAGMENT FIBROBLAST GROWTH FACTOR 21 FUSION PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; HAPLORHINI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN ENGINEERING; SINGLE DRUG DOSE; TREATMENT OUTCOME; WEIGHT GAIN; WILD TYPE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOGLYCEMIC AGENTS; MACACA FASCICULARIS; MALE; MICE; MUTATION; PROTEIN ENGINEERING; PROTEOLYSIS; RECOMBINANT FUSION PROTEINS;

MACACA FASCICULARIS; MUS;

EID: 84870278211     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049345     Document Type: Article

References (26)

1. Long YC, Kharitonenkov A, (2011) Hormone-like fibroblast growth factors and metabolic regulation. Biochim Biophys Acta 1812: 791-795.
2. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635.
3. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-781.
4. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, et al. (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297: E1105-1114.
5. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-259.
6. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E, (2009) Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150: 4931-4940.
7. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, et al. (2009) Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150: 4625-4633.
8. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Koster A, et al. (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55: 2470-2478.
9. Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, et al. (2009) Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150: 4084-4093.
10. Zhang Y, Lei T, Huang JF, Wang SB, Zhou LL, et al. (2011) The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol 342: 41-47.
11. Chau MD, Gao J, Yang Q, Wu Z, Gromada J, (2010) Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A 107: 12553-12558.
12. Sarruf DA, Thaler JP, Morton GJ, German J, Fischer JD, et al. (2010) Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59: 1817-1824.
13. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027.
14. Veniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, et al. (2012) Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys. Endocrinology 153: 4192-4203.
15. Yie J, Hecht R, Patel J, Stevens J, Wang W, et al. (2009) FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 583: 19-24.
16. Hall MP, Gegg C, Walker K, Spahr C, Ortiz R, et al. (2010) Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J 12: 576-585.
17. Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, et al. (2011) Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 6: e18398.
18. Stein S, Bachmann A, Lossner U, Kratzsch J, Bluher M, et al. (2009) Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32: 126-128.
19. Carter PJ, (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317: 1261-1269.
20. Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, et al. (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27: 3417-3428.
21. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, et al. (2008) FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 215: 1-7.
22. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, et al. (2007) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 104: 7432-7437.
23. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, et al. (2009) Different roles of N- and C- termini in the functional activity of FGF21. J Cell Physiol 219: 227-234.
24. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, et al. (2002) Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143: 3179-3182.
25. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, et al. (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60: 2079-2086.
26. Garringer HJ, Malekpour M, Esteghamat F, Mortazavi SM, Davis SI, et al. (2008) Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis. Am J Physiol Endocrinol Metab 295: E929-937.